EUCTR2016-003202-14-HU进行中（未招募）1 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PERSPECTIVE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •* Histologically confirmed diagnosis of follicular lymphoma CD20+
- •(Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease.
- •* Measurable disease
- •* Subjects 70 years of age or older; OR subjects 60-69 years of age who
- •have one or more comorbidities.
- •* Meets one or more Groupe d'Etude des Lymphomes Folliculaire (GELF)
- •* Adequate hematologic function within protocol-defined parameters.
- •* Adequate hepatic and renal function within protocol-defined
- •parameters.
- •* ECOG performance status score of 0-2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •* Transformed lymphoma
- •* Prior treatment for follicular lymphoma
- •* Central nervous system lymphoma or leptomeningeal disease
- •* Currently active, clinically significant cardiovascular disease
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to test the safety and effectiveness of aripiprazole against placebo in children and adolescents with Tourette’s DisorderEUCTR2012-003488-23-BEOtsuka Pharmaceutical Development & Commercialization, Inc.67
进行中（未招募）
1 期
A Clinical Study of Rituximab with Ibrutinib Compared to Rituxumab Alone, and Subsequently of Ibrutinib Alone Compared to Placebo in Treatment Naïve Subjects with Follicular LymphomaFollicular lymphomaMedDRA version: 24.0Level: LLTClassification code 10029473Term: Nodular (follicular) lymphomaSystem Organ Class: 100000004864EUCTR2016-003202-14-GRPharmacyclics LLC440
进行中（未招募）
1 期
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus ErythematosusMedDRA version: 18.1 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2014-005000-19-HUJanssen-Cilag International N.V.134
招募中
1 期
Study to Evaluate Safety, Tolerability and Efficacy in patients with Primary Biliary Cholangitis of Saroglitazar Magnesium-III (EPICS-III).EUCTR2022-001634-10-ISZydus Therapeutics Inc.192
进行中（未招募）
1 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis - NAPsoriatic ArthritisEUCTR2004-003298-10-GBCentocor BV